A Phase I Feasibility And Safety Study of Fluorescein-Specific (FITC-E2) CAR T Cells In Combination With Parenterally Administered Folate-Fluorescein (UB-TT170) For Osteogenic Sarcoma
Clinical trial NCT05312411 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05312411
- Sponsor
- Seattle Children's Hospital
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-05-20
- Primary completion
- 2025-03-12
- Enrollment
- 21
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.